Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$108.70 USD

108.70
9,520,162

-1.05 (-0.96%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion

Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.

Merck's Pediatric Filings for Dificid Get FDA's Priority Review

The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.

Why Merck (MRK) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA

AstraZeneca (AZN) gets CRL from the FDA for PT010, its triple-combo inhaler to treat COPD.

Merck Sees Hammer Chart Pattern: Time to Buy?

Merck has been struggling lately, but the selling pressure may be coming to an end soon.

Merck (MRK) Stock Moves -0.68%: What You Should Know

Merck (MRK) closed the most recent trading day at $83.61, moving -0.68% from the previous trading session.

Immunomedics (IMMU) Reports Interim Urothelial Cancer Data

Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.

Seattle Genetics Up on Positive Data From Bladder Cancer Study

Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.

AstraZeneca/Merck's Lynparza Positive in Prostate Cancer Study

AstraZeneca's (AZN) Lynparza doubled the time without radiographic disease progression in a study evaluating in an advanced prostate cancer patient population.

Glaxo's Zejula Betters PFS in First-Line Ovarian Cancer Study

Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer significantly reduces risk of disease progression or death by 38%.

AstraZeneca/Merck's Lynparza Improves PFS in Frontline Study

AstraZeneca's (AZN) Lynparza reduces the risk of disease progression by 41% in a study, evaluating the PARP inhibitor as a first-line maintenance treatment in women with advanced ovarian cancer.

AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug

AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.

IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA

IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.

Medicines Company's Inclisiran Succeeds in Pivotal Studies

The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in the remaining two phase III studies in the ORION program. Shares up.

Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late

Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

Here's Why AstraZeneca (AZN) is Outperforming Its Industry

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

Tyme Initiates Pivotal Stage of Pancreatic Cancer Study

Tyme (TYME) initiates the pivotal stage of the TYME-88-Panc study evaluating oral SM-88 (racemetyrosine) for third-line treatment of patients with metastatic pancreatic cancer.

The Zacks Analyst Blog Highlights: Procter & Gamble, Visa, United Technologies, Walmart and Merck

The Zacks Analyst Blog Highlights: Procter & Gamble, Visa, United Technologies, Walmart and Merck

BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors

BioLineRx (BLRX) starts dosing the first patient in the part 2 of the phase I/IIa study evaluating AGI-134 for solid tumors.

Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study

Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.

Bristol-Myers' Opdivo Gains Positive CHMP View for New Dose

Bristol-Myers (BMY) receives a positive response from the CHMP for a four-week dosing option with Opdivo as an adjuvant treatment of adult patients with melanoma.

Nalak Das headshot

5 Top Dow Stocks to Buy on the Dip for a Stronger Portfolio

A fundamentally stable U.S. economy, which is growing for history setting 11 years, albeit at a slow pace and a dovish Fed in 2019 are the two major drivers of the Dow.

Merck (MRK) Dips More Than Broader Markets: What You Should Know

Merck (MRK) closed the most recent trading day at $83.63, moving -0.87% from the previous trading session.

Clovis Gains Rights to Pre-Clinical Cancer Program for $12M

Clovis (CLVS) enters into licensing and collaboration agreement with 3B Pharmaceuticals and acquires rights to FAP targeted radiopharmaceutical therapy for developing new cancer treatments.

Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids

Glaxo's (GSK) SLE drug Benlysta gets a favorable CHMP opinion that recommends an approval for intravenous formulation in pediatric patients.